Photo illustration: Axios Visuals. Photo: Courtesy of Cooley
The cloud of pharma tariffs hangs over biopharma, and companies need to start preparing now, says Cooley partner Amanda Main.
Why it matters: Uncertainty has slowed dealmaking in H1 and could continue to dampen dealmaking in the back half of the year.
